InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPRGet Rating) in a report issued on Monday. The brokerage set a “sell” rating on the stock.

InspireMD Stock Performance

Shares of InspireMD stock opened at $1.14 on Monday. The stock has a market capitalization of $9.50 million, a P/E ratio of -0.50 and a beta of 1.06. InspireMD has a 52-week low of $0.81 and a 52-week high of $3.85. The stock’s 50-day simple moving average is $1.29 and its 200 day simple moving average is $1.74.

InspireMD Company Profile

(Get Rating)

InspireMD, Inc, a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery.

Recommended Stories

Receive News & Ratings for InspireMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD and related companies with MarketBeat.com's FREE daily email newsletter.